Investigating Age Differences in COVID-19 Immune Response
Dr. Cheng’s team identified several differences in immune and inflammatory responses that may help explain the elevated risk for severe illness and death observed in older COVID-19 patients.
Advancing Breast Cancer Prevention Strategies
With a grant from the American Cancer Society, Dr. Karaayvaz’s team will investigate the molecular connections linking BRCA2 to breast cancer development with the goal of developing innovative strategies for breast cancer risk assessment and prevention.
Harnessing Endophenotypes for Alzheimer’s Disease Drug Repurposing
Dr. Cheng’s team developed an endophenotype-based drug repurposing methodology that identified the FDA-approved drug sildenafil as a candidate for the prevention and treatment of Alzheimer’s disease.
Investigating the Influence of Genetic Ancestry on Colorectal Cancer Outcomes
Dr. Schmit’s team will study the role of genetic ancestry in shaping immune-related determinants of colorectal cancer outcomes.
Establishing the Cleveland Clinic Breast Cancer Center of Excellence
Led by Drs. Keri and Eng, the center will support a multi-investigator research team focused on discerning the role of the tumor microenvironment in breast cancer progression.
GMI Researchers Win 2021 Lerner Research Institute Awards for Excellence
Drs. Eng and Sarn were recognized for their outstanding achievements.
NIH Supplement Award for Alzheimer’s Disease Drug Repurposing
With this award, Dr. Cheng’s team will develop artificial intelligence and machine learning tools capable of identifying novel endophenotypes and actionable targets for drug repurposing in Alzheimer’s disease.
Developing Artificial Intelligence Tools for Alzheimer’s Disease Drug Discovery
With a new $4 million grant, Drs. Cheng, Bekris and Leverenz will develop and utilize artificial intelligence tools to identify novel drug targets and repurposable drugs for Alzheimer’s disease.
National Institute on Aging Awards $15.4 Million to Continue Support for Cleveland Alzheimer’s Disease Research Center
The multi-institution collaboration, which includes Dr. Bekris’ team, aims to accelerate research for Alzheimer’s disease and related dementias.
Artificial Intelligence Predicts Cancer Therapy-Related Cardiac Risk
A research team led by Drs. Cheng and Collier developed an artificial intelligence methodology to help identify cancer patients at risk for cancer therapy-related cardiac dysfunction.
Investigating Sex Differences in COVID-19 Immune Response
Utilizing large-scale patient data and samples from the Cleveland Clinic COVID-19 registry, Dr. Cheng’s team identified clinical characteristics and immune-related mechanisms associated with sex differences in COVID-19 outcomes.
Predicting Cognitive Performance in People with HIV
Dr. Kallianpur’s team found that higher levels of the iron-delivery proteins heavy-chain ferritin and transferrin predict better cognitive outcomes in people with HIV, independent of factors like inflammation, over an extended period of follow-up.
Characterizing the Genetic Architecture of Parkinson’s Disease in Latinos
To address the lack of diversity in Parkinson’s disease genetic research, Dr. Mata and colleagues conducted the first ever genome-wide association study of Latino Parkinson’s disease patients from South America.
GMI Researchers Receive Awards Promoting Diversity in Science
Dr. Cheng and Ms. Castrillon Lal received the Gilliam Fellowship for Advanced Study, and Dr. Smith received the MOSAIC Postdoctoral Career Transition Award to Promote Diversity.
Study Establishes Maternal Genetics as Modulator of Autism Risk
A preclinical study led by Dr. Eng indicates that maternal genetics alone may contribute to increased risk for autism spectrum disorder in offspring.
Artificial Intelligence Methodology for Alzheimer’s Disease Drug Repurposing
Dr. Cheng’s team developed an artificial intelligence methodology to uncover molecular targets involved in neuroinflammation and identify candidate therapeutics for Alzheimer’s disease.
Predicting Efficacy and Safety of COVID-19 Vaccines in Cancer Patients
Dr. Eng has received a Caregiver Catalyst Grant to assess the efficacy and safety of the current COVID-19 mRNA vaccines in individuals with cancer or a high genetic susceptibility to cancer due to heritable PTEN mutations.
GMI Postdocs Receive National Hemophilia Foundation Fellowship Awards
With their awards, Drs. Srivastava and Zhang will study the blood-clotting protein factor VIII.
Network Medicine Links COVID-19 and Alzheimer’s Disease-like Cognitive Impairment
Utilizing network medicine methodologies, a research team led by Dr. Cheng linked COVID-19 to neuroinflammation and brain microvascular injury in Alzheimer’s disease-like cognitive impairment.
Breast Microbiome-Immune Interactions May Influence Breast Cancer
Dr. Eng and colleagues found that the breast microbiome may modulate local immune responses that lead to breast cancer.
Study Links Gene Variant with Alzheimer’s Disease Resilience
Dr. Bekris’ team has found that Alzheimer’s disease resilience may be modulated by interactions between a TNFRSF1B gene variant and the protein sTNFR2.
Precision Medicine in Migraine Treatment
With their Co-Laboratories Award, Drs. Mata and Ahmed will team up to develop a way to predict patient response to FDA-approved treatments for migraine prevention.
Researchers to Study Genetics of Focal Cortical Dysplasia with New NIH Grant
Dr. Lal’s team will perform the most comprehensive genetic analysis of focal cortical dysplasia (FCD) to confirm proposed FCD-associated genes and identify novel FCD causal genes and variants.
Cancer Genetics Researchers Receive VeloSano Awards
These awards provide Drs. Eng, Lal and Lesmana with seed funding for their highly innovative and potentially impactful cancer research projects.